Impact of ATO on the outcome of newly diagnosed APL. (A) Impact of ATO-containing induction (ATRA/IV-ATO and oral-AAA) on 60-day survival compared with ATRA/chemotherapy induction. P values were .02 on univariate analysis and <.001 on multivariate analysis. (B) Impact of ATO-containing induction (ATRA/IV-ATO and oral-AAA) on RFS, compared with ATRA/chemotherapy induction. P values on both univariate and multivariate analysis were <.001. (C) Impact of ATRA/chemotherapy/ATO maintenance, ATRA/IV-ATO, and frontline oral-AAA groups on RFS compared with ATRA/chemotherapy/non-ATO maintenance. P values on both univariate and multivariate analysis were <.001. (D) Impact of ATO-containing induction (ATRA/IV-ATO and oral-AAA) on OS, compared with the ATRA/chemotherapy induction. P value was .08 on univariate analysis and .03 on multivariate analysis.